Key Leaders’ Opinion on Novel Progress in Diagnosis and Treatment of Bladder Cancer
Editors: | Qing Zou, Zengjun Wang, Ming Chen, Bhaskar K. Somani, Alberto Martini |
Publisher: AME Publishing Company; 1st edition (2019)
ISBN: 978-988-79497-5-6
Hardcover: 182 pages
Language: English
Available at:
Key Leaders' Opinion on Novel Progress in Diagnosis and Treatment of Bladder Cancer is a collection of recently published papers by international experts in the field of bladder cancer. This series highlights the advancements in the molecular biology, surgical technique and novel therapeutic options for patients with bladder cancer. Furthermore, this series highlights the importance of a multi-disciplinary approach to treating patients with bladder cancer. In this series you will find highlights associated with systemic therapy, surgical care as well as nursing care. Specifically, you will find six sections each summarizing the recent important contributions to bladder cancer by my esteemed colleagues. The Precision Medicine for Individualized Therapy section discusses the evolution in understanding the molecular biology and genetics of both non-muscle and muscle invasive bladder cancer. This section identifies the most recent genetics in bladder cancer, which can be used to help us to better understand the machinery that drives this disease and to identify biomarkers to better risk stratification our patients. Novel Advances in Surgical Technology and Debates and Experience in Traditional Surgical Treatment discuss the innovations in surgical techniques and how their use has improved the morbidity associated with surgical care of bladder cancer patients. The sections; Progress in Chemotherapy and Medical Treatment and Fresh Vision of Pathogenesis and Development and Prognosis summarizes recent improvements on how we should approach treating bladder cancer patients. Lastly, the most important section, Experience and Exploration in Clinical Nursing, highlights the importance of a multi-disciplinary approach to treating bladder cancer patients.
HONORARY EDITORS
Vincenzo Ficarra | Department of Human and Paediatric Pathology “Gaetano Barresi”, Urologic Section, University of Messina, Messina, Italy |
John P. Sfakianos | Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA |
EDITORS
Qing Zou | Department of Urologic Surgery, Jiangsu Cancer Hospital& Jiangsu Institute of Cancer Research & Affiliated CancerHospital of Nanjing Medical University, Nanjing, China |
Zengjun Wang | Department of Urology, the First Affiliated Hospital ofNanjing Medical University, Nanjing, China |
Ming Chen | Department of Urology, Affiliated Zhongda Hospital ofSoutheast University, Nanjing, China |
Bhaskar K. Somani | Department of Urology, University Hospital SouthamptonNHS Trust, Southampton, UK |
Alberto Martini | Department of Urology, Vita-Salute San RaffaeleUniversity, Milan, Italy; Department of Urology, IcahnSchool of Medicine at Mount Sinai, New York, USA |
ASSOCIATE EDITORS
Ninghong Song | Department of Urology, the First Affiliated Hospital ofNanjing Medical University, Nanjing, China |
Xiao Li | Department of Urologic Surgery, Jiangsu Cancer Hospital& Jiangsu Institute of Cancer Research & Affiliated CancerHospital of Nanjing Medical University, Nanjing, China |
Stéphane Culine | Department of Medical Oncology, Hôpital Saint-Louis,AP-HP, and Paris-Diderot University, Paris, France |